Clinical Trial Update: A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of guselkumab and golimumab for active psoriatic arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Simponi (golimumab)
• TREMFYA (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthritis, Psoriatic | Phase 2 | Status: COMPLETED